These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9795881)

  • 1. Characterization of the dose-dependent time of peak effect in indirect response models.
    Majumdar A
    J Pharmacokinet Biopharm; 1998 Apr; 26(2):183-206. PubMed ID: 9795881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.
    Minto CF; Schnider TW; Gregg KM; Henthorn TK; Shafer SL
    Anesthesiology; 2003 Aug; 99(2):324-33. PubMed ID: 12883405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions.
    Krzyzanski W; Jusko WJ
    J Pharmacokinet Biopharm; 1998 Aug; 26(4):385-408. PubMed ID: 10214559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of four basic models of indirect pharmacodynamic responses.
    Sharma A; Jusko WJ
    J Pharmacokinet Biopharm; 1996 Dec; 24(6):611-35. PubMed ID: 9300353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect pharmacodynamic response models do not require any parametric pharmacokinetic model to be fitted to effect-time data.
    Piotrovsky VK
    Methods Find Exp Clin Pharmacol; 1997 Dec; 19(10):723-9. PubMed ID: 9542723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-based minibolus delivery as an alternative to continuous infusion for drugs that exhibit a biophase lag.
    Kern SE; Westenskow DR
    J Pharmacokinet Biopharm; 1997 Apr; 25(2):191-208. PubMed ID: 9408859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic modelling of insulin: comparison of indirect pharmacodynamic response with effect-compartment link models.
    Lin S; Chien YW
    J Pharm Pharmacol; 2002 Jun; 54(6):791-800. PubMed ID: 12078995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.
    Gumbleton M; Oie S; Verotta D
    Br J Clin Pharmacol; 1994 Nov; 38(5):389-400. PubMed ID: 7893578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mathematical formalism for the properties of four basic models of indirect pharmacodynamic responses.
    Krzyzanski W; Jusko WJ
    J Pharmacokinet Biopharm; 1997 Feb; 25(1):107-23. PubMed ID: 9353696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena.
    Sharma A; Ebling WF; Jusko WJ
    J Pharm Sci; 1998 Dec; 87(12):1577-84. PubMed ID: 10189270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic modelling: history and perspectives.
    Csajka C; Verotta D
    J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):227-79. PubMed ID: 16404503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
    Deschamps C; Dubruc C; Mentre F; Rosenzweig P
    Clin Pharmacol Ther; 2000 Dec; 68(6):647-57. PubMed ID: 11180025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic/Pharmacodynamic Analysis of Metformin using Different Models in Diabetic Rats.
    Li X; Chen Y; Zhao Z; Lu W; Zhou T
    Drug Res (Stuttg); 2016 Oct; 66(10):547-554. PubMed ID: 27463030
    [No Abstract]   [Full Text] [Related]  

  • 15. Note: caution in use of empirical equations for pharmacodynamic indirect response models.
    Krzyzanski W; Jusko WJ
    J Pharmacokinet Biopharm; 1998 Dec; 26(6):735-41. PubMed ID: 10485083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles.
    Gabrielsson J; Jusko WJ; Alari L
    Biopharm Drug Dispos; 2000 Mar; 21(2):41-52. PubMed ID: 11100906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between steady-state and single-dose plasma drug concentrations for pharmacokinetic systems with nonlinear elimination.
    Cheng HY; Jusko WJ
    Biopharm Drug Dispos; 1989; 10(5):513-28. PubMed ID: 2804255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The connection between the steady state (Vss) and terminal (Vbeta) volumes of distribution in linear pharmacokinetics and the general proof that Vbeta >/= Vss.
    Berezhkovskiy LM
    J Pharm Sci; 2007 Jun; 96(6):1638-52. PubMed ID: 17117429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.